Downregulation of EZH2 inhibits epithelial-mesenchymal transition in enzalutamide-resistant prostate cancer.

Zhuang-Zhuang ZhangXinyi WangMiyeong KimDaheng HeChi WangKa Wing FongXiaoqi Liu

Published in: The Prostate (2023)

We identified the novel roles of EZH2 in EnzR mCRPC. EnzR PCa gains more EMT properties than that of enzalutamide-sensitive PCa. Loss of EZH2-assocaited inhibition of EMT is PRC2 independent. Downregulation of EZH2 suppresses EMT by impairing formation of H3K4me3 at the promotor regions, thus repressing expression of EMT-associated TFs.

Keyphrases

epithelial mesenchymal transition
prostate cancer
signaling pathway
transforming growth factor
long noncoding rna
long non coding rna
radical prostatectomy
poor prognosis
cell proliferation